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Mr A. was a 20-yr-old white male with no medical
history of note. His GP, who was concerned about
his poor psychosocial functioning, referred him to a
specialist service oﬀering advice and support for
young people at risk for psychosis.
On assessment he reported daily paranoid exper-
iences such as ‘sensing’ the thoughts of strangers
passing him on the street, next-door-neighbours and
family members. He also reported occasional visual
and tactile hallucinations. The frequency and severity
of these symptoms did not reach DSM-IV criteria for
schizophrenia or other psychotic disorders [Positive
and Negative Symptoms Scale (PANSS) scores: posi-
tive 16, negative 8, general 35; Global Assessment
of Functioning (GAF) scale total score 55]. These
attenuated psychotic symptoms met operationalized
criteria for an ‘at risk mental state’ (ARMS) assessed
using a validated structured assessment (Yung et al.,
2002). People with an ARMS have a very high risk of
developing a psychotic disorder in the next 1–2 yr
(Yung et al., 2003). Mr A.’s overall level of function
was low, as scored on the GAF scale (GAF 55; highest
function 100). Neuropsychological assessment indi-
cated a normal level of performance in all cognitive
domains tested with the exception of verbal learning
(as indexed by the Auditory Verbal Learning Test).
Over the ensuing 17 months Mr A.’s psychotic symp-
toms becamemore severe, with the emergence of frank
persecutory delusions and marked formal thought
disorder (and increased PANSS scores: positive 43,
negative 18, general 22), and a further decline in his
psychosocial function (GAF score fell by 20 points
to 35). The clinical picture at this point met DSM-IV
criteria for schizophrenia. He was admitted to an
in-patient ward and treated with oral aripiprazole
(15 mg o.d.). Although his symptoms subsequently
improved, residual symptoms and functional impair-
ment prevented him from returning to work.
Mr A. underwent ﬂuoro-dopa (F-DOPA) positron
emission tomography (PET) when he ﬁrst presented
with an ARMS and was scanned again shortly after he
developed schizophrenia. The PET scanning was
carried out using a 3D PET scanner (ECAT/EXACT
3D; Siemens/CTI, Knoxville, TN, USA), which has a
spatial resolution of 4.8¡0.2 mm and a sensitivity of
69 cps/Bq.ml. The subject received 150 mg carbidopa
and 400 mg entacapone orally 1 h prior to scanning to
reduce the formation of radiolabelled metabolites. A
5-min transmission scan was carried out before radio-
tracer injection using a 150-MBq 137Cs rotating point
source to correct for attenuation and scatter. Approxi-
mately 150 MBq of F-DOPA were administered by
intravenous injection immediately following a 30-s
background frame. The region-of-interest (ROI) ana-
lysis was carried out blind to clinical status by one
investigator. A graphical analysis was used to calcu-
late inﬂux constants (Ki values) for the whole striatal
ROI. The cerebellum was used as the reference region
as this has been shown to have the lowest F-DOPA
uptake in the brain.
We also examined Mr A.’s frontal lobe function
using functionalmagnetic resonance imaging (fMRI) in
conjunction with a working-memory task at the same
time-points (before and after the onset of psychosis).
Images were acquired on a 1.5 T Signa (GE) system at
the Maudsley Hospital, London. T2*-weighted images
were acquired with a TR of 2000 ms and TE 40 ms,
with a 0.3 mm gap in 14 axial planes parallel to the
intercommissural (AC–PC) line. During the working-
memory (n-back) task the subject is presented with
series of letters that are viewed using a prismatic
mirror and is required to move a joystick to the left
when the letter ‘X’ appears (o-back) or when the cur-
rently presented letter is the same as that presented n
trials (n-back) previously. Images were analysed with
SPM5. The onset times (in seconds) for each trial were
convolved with a canonical haemodynamic response
function. Active task condition (n-back) was then
contrasted against the baseline condition (‘ is it X?’).
To test our hypothesis that there were diﬀerences
between the two time-points reﬂecting the develop-
ment of acute psychosis, the activation for the task
(n-back>baseline) was then compared between the
two time-points (ARMS and psychosis onset). Whole-
brain voxel-wise threshold was set at p<0.05 family-
wise error (FWE)-corrected.
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The PET scans showed that following the develop-
ment of schizophrenia there was an increase in striatal
dopamine function, from baseline values (Figure 1) to
a level similar to that seen in established schizophrenia
(Howes et al., in press;McGowan et al., 2004). Previous
molecular-imaging studies indicate that schizophrenia
is associated with increased striatal pre-synaptic
dopaminergic function, and elevated synaptic levels
and release of dopamine in the striatum (reviewed
in McGuire et al., 2008). The observed dopamine ab-
normalities may underlie the phenomenology of the
prodromal symptoms (McGuire et al., 2008).
However, the increase in this case was within the
test–retest variability of [18F]DOPA 3D PET Ki values,
reported to be 2–4% in the putamen and 0–11% in the
caudate (Weinhard, 1998). Longitudinal studies of a
group of ARMS subjects will be required to determine
if there is a statistically signiﬁcant increase in Ki value.
A power calculation using the data reported here
indicates that a sample size of at least 7 is required for
future longitudinal studies.
Mr A. had received 4 wk treatment with 15 mg/d
aripiprazole prior to the follow-up PET scanning.
A few days of treatment with antipsychotic drugs
increases F-DOPA uptake but 5 wk treatment with
haloperidol has been found to decrease F-DOPA
uptake (Grunder et al., 2003; Vernalaken et al., 2006),
suggesting that if we had been able to measure the
Ki value immediately before treatment commenced it
may have been higher.
The fMRI scans showed that transition to psychosis
was associated with a longitudinal reduction of the
task-related activation in the right dorsolateral pre-
frontal cortex (DLPFC), a cortical region which is
normally engaged during this task. Reduced activation
in the prefrontal cortex has been widely observed in
patients with schizophrenia and is thought to underlie
the pervasive cognitive impairment seen in the illness
(Fusar-Poli et al., 2007). The disruption of prefrontal
functioning may reﬂect a meso-cortical modulation of
neural activity in this region by striatal dopamine
(Floresco and Magyar, 2006). In particular, there is
evidence that the associative part of the striatum is
connected with the DLPFC and that dopamine levels
in such striatal regions are associated with/related
to cognitive functioning (Cropley et al., 2006), and
speciﬁcally with working memory (Tanaka, 2006).
This case study indicates that the pathophysiology
of developing psychosis involves the progression
of striatal hyperdopaminergia, working-memory dys-
function and prefrontal cortical dysfunction. Although
conclusions are methodologically limited by it being a
single within-group case and despite the test–retest
liability in functional imaging indicating that larger
samples are needed to obtain reliable results, this
report suggests that future studies should investigate
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Figure 1. Positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) in the same subject before and
after the onset of psychosis. Left of the picture: n-back working-memory task (above) and fMRI (below); brain activity in the
prefrontal cortex during the mnemonic task (one-back and two-back>baseline) over time (before>after the onset of
psychosis) in a within-subject design (voxel p>0.05 family-wise error). Right of the picture: PET, [18F]ﬂuoro-DOPA images
which evidence an increase of striatal dopamine from the prodromal phases (pre) to the onset of psychosis (post). Inﬂux
constants (Ki) were calculated from region-of-interest (ROI)-derived time–activity curves using Patlak analysis with a cerebellar
reference region following frame-by-frame movement correction.
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the relationship between these factors. Furthermore,
it shows that it is possible to conduct multimodal
imaging during the prodromal ﬁrst psychotic phases
of schizophrenia, and that the combination of imaging
techniques has the potential to delineate the causal
relationships between key pathophysiological pro-
cesses in the evolution of schizophrenia. The obser-
vation that transition to psychosis is associated with
abnormalities of prefrontal function and striatal dop-
amine raises the possibility that multimodal neuro-
imaging techniques could be used to identify the core
pathophysiological changes underlying the disorder
onset. The PET fMRI evidence that presynaptical
striatal dopamine and working-memory function is
perturbed in the prodromal phase of schizophrenia
provides a biological rationale to support the intro-
duction of anti-dopaminergic preventive intervention
in people at high risk of psychosis (McGlashan et al.,
2006; McGorry et al., 2002).
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